
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Oculis Holding AG Warrants (OCSAW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: OCSAW (3-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 75.18% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.85 - 11.50 | Updated Date 02/26/2025 |
52 Weeks Range 1.85 - 11.50 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Oculis Holding AG Warrants
Company Overview
History and Background
Oculis Holding AG is a biopharmaceutical company dedicated to developing innovative ophthalmic treatments. While specific warrant history requires real-time data lookup, warrants are typically issued in conjunction with a SPAC merger or financing rounds to provide investors with the right to purchase shares at a specified price.
Core Business Areas
- Pharmaceutical Development: Focuses on developing and commercializing innovative ophthalmic treatments for various eye diseases.
Leadership and Structure
Leadership details and organizational structure unavailable without real-time data lookup. Typically, a warrant issuing company has a board of directors and executive management team.
Top Products and Market Share
Key Offerings
- OCU400: A novel therapy addressing genetic retinal diseases; Market share data is not yet established. Potential competitors include companies developing gene therapies for retinal diseases.
- OCU200: Investigational treatment for dry eye disease; Market share data is not yet established. Competitors include Allergan (ABBV) (Restasis), Novartis (NOVN) (Xiidra) and other companies with dry eye products.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is experiencing growth driven by aging populations, increasing prevalence of eye diseases, and advancements in treatment options, particularly in gene and cell therapies.
Positioning
Oculis Holding AG aims to be a leader in ophthalmic innovation through novel treatments for unmet needs.
Total Addressable Market (TAM)
The global ophthalmology market is estimated to be worth billions of dollars. Oculis is positioning itself to capture a portion of this TAM through its novel therapies.
Upturn SWOT Analysis
Strengths
- Innovative pipeline of ophthalmic treatments
- Focus on unmet medical needs
- Potential for breakthrough therapies
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- Requires significant capital for R&D
Opportunities
- Expanding ophthalmic market
- Partnerships with larger pharmaceutical companies
- Regulatory approvals for novel therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Generic drugs eating up market share from novel therapies
Competitors and Market Share
Key Competitors
- ABBV
- NOVN
- ALNY
- LLY
Competitive Landscape
Oculis Holding AG aims to compete with established players by developing innovative ophthalmic therapies. Its success depends on clinical trial outcomes and regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data unavailable without access to financial reports.
Future Projections: Future projections depend on clinical trial results, regulatory approvals, and market adoption.
Recent Initiatives: Recent initiatives likely include clinical trial advancements and potential partnerships.
Summary
Oculis Holding AG is a biopharmaceutical company focused on ophthalmic diseases. They are in the early stages of commercialization, having innovative therapies in development. Their long-term success hinges on clinical trial results and regulatory approvals. The company faces competition from larger, established pharmaceutical companies and needs to manage its cash flow carefully while advancing its pipeline. Warrant valuation depends on the stock reaching the strike price.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are based on available information and may be subject to change. Warrant value is speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-03 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website |
Full time employees 32 | Website |
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.